Takeda teams with enGene for gastrointestinal R&D

Japanese drugmaker Takeda signed a deal with enGene to spotlight new therapies for gastrointestinal disease. Under the agreement, enGene will develop two treatments matching up to Takeda-selected targets through preclinical studies, and the major drugmaker will take the reins from there, promising its partner an upfront payment and milestones tied to R&D. Release